Los Angeles Capital Management’s Taysha Gene Therapies TSHA Stock Holding History

Los Angeles Capital Management’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$219K	Buy	32,149 +3,638	+13%	+$21.5K	﹤0.01%	1149
2026 Q1	$127K	Sell	28,511 -4,407	-13%	-$20.5K	﹤0.01%	1273
2025 Q4	$162K	Buy	+32,918	New	+$160K	﹤0.01%	1303
2025 Q3	–	Sell	-117,740	Closed	-$272K	–	1537
2025 Q2	$272K	Sell	117,740 -25,070	-18%	-$54.5K	﹤0.01%	1088
2025 Q1	$199K	Buy	142,810 +5,350	+4%	+$8.95K	﹤0.01%	1013
2024 Q4	$238K	Sell	137,460 -69,532	-34%	-$144K	﹤0.01%	1008
2024 Q3	$416K	Buy	+206,992	New	+$454K	﹤0.01%	914

Other funds holding TSHA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Los Angeles Capital Management's TSHA Position: Q2 2026 in Review

Los Angeles Capital Management increased its Taysha Gene Therapies (TSHA) stake by 13% in Q2 2026, buying an estimated $21.5K and bringing the position to 32,149 shares worth $219K. The position accounts for ﹤0.01% of the portfolio, ranked #1149.

Los Angeles Capital Management first reported a position in TSHA in Q3 2024 and has held it in 7 quarters since. The position peaked at $416K in Q3 2024. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

Los Angeles Capital Management held 32,149 shares of Taysha Gene Therapies worth $219K as of Q2 2026.
Los Angeles Capital Management bought 3,638 Taysha Gene Therapies shares in Q2 2026, an estimated $21.5K.
Taysha Gene Therapies made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #1149 holding.
Los Angeles Capital Management first reported a position in Taysha Gene Therapies in Q3 2024 and has held it in 7 quarters since.
Los Angeles Capital Management's Taysha Gene Therapies position peaked at $416K in Q3 2024.
208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.